Clinical Scorecard: Decreased REST Levels Linked to Alzheimer's Disease Pathology Are Improved by NAD+
At a Glance
Category
Detail
Condition
Alzheimer's disease (AD)
Key Mechanisms
Downregulation of REST contributes to AD pathology via increased amyloid-β and phosphorylated Tau deposition; NAD+/SIRT1 axis modulates REST expression affecting mitophagy and synaptic function
Target Population
Individuals with Alzheimer's disease and age-related cognitive decline
Care Setting
Neurology and neurodegenerative disease clinical settings
Key Highlights
REST downregulation and altered localization contribute to AD pathology in entorhinal cortex and hippocampus.
REST overexpression improves cognition, reduces amyloid-β and phosphorylated Tau, and restores mitochondrial and synaptic homeostasis.
NAD+/SIRT1 axis regulates REST expression via chromatin remodeling, influencing genes involved in mitophagy and synaptic function.
Guideline-Based Recommendations
Diagnosis
Assess REST expression levels and localization in brain regions affected by AD (entorhinal cortex, hippocampus) as potential biomarkers.
Management
Consider therapeutic strategies aimed at increasing REST expression or activity to mitigate AD pathology.
Utilize NAD+ supplementation or NAD+ precursors to enhance SIRT1 activity and restore REST-mediated neuroprotection.
Monitoring & Follow-up
Monitor cognitive function and biomarkers of amyloid-β and phosphorylated Tau deposition during REST-targeted therapies.
Evaluate mitochondrial function and mitophagy markers as indicators of treatment efficacy.
Risks
Potential unknown risks associated with manipulating REST levels and NAD+/SIRT1 axis require further clinical evaluation.
Patient & Prescribing Data
Patients with Alzheimer's disease exhibiting cognitive decline and mitochondrial dysfunction
NAD+ supplementation elevates SIRT1 levels, enhances REST expression, restores mitophagy, reduces amyloid-β and Tau pathology, and improves memory retention.
Clinical Best Practices
Target REST upregulation as a neuroprotective strategy in AD management.
Incorporate NAD+ precursor supplementation to activate the NAD+/SIRT1/REST pathway.
Focus on maintaining mitochondrial health and mitophagy to slow AD progression.
